CORTI, CHIARA
CORTI, CHIARA
Dipartimento di Oncologia ed Emato-Oncologia
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
2025 P.P.M. Berton Giachetti, S. Morganti, S. Gandini, F. Giudici, A. Marra, E. Nicolò, E. Zattarin, C. Corti, L. Boldrini, A. Verrazzo, C. Sposetti, M.G. Razeti, A. Carnevale Schianca, R. Scafetta, B. Taurelli Salimbeni, A. Esposito, P. Zagami, D. Trapani, B. Malagutti, R. Caputo, C. Vernieri, E. Munzone, S. Scagnoli, A. Botticelli, M. Lambertini, M. Giuliano, M. De Laurentiis, G. Viale, G. Bianchini, G. Curigliano, C. De Angelis, C. Criscitiello
PS3-08-29: Retrospective study evaluating eligibility, treatment patterns, and clinicopathologic factors associated with adjuvant abemaciclib use in patients with high-risk estrogen receptor-positive (ER+) HER2-negative (HER2-) early breast cancer (EBC).
2025 C. Corti, N. Zhou, A. Martin, C. Stever, T. Parker, C. Snow, G. Curigliano, T. King, E. Mittendorf, N. Lin, N. Tayob, S. Tolaney
Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing
2025 C. Corti, H.S. Rugo, S.M. Tolaney
Estrogen Signaling in Early-Stage Breast Cancer: Impact on Neoadjuvant Chemotherapy and Immunotherapy
2025 C. Corti, B. Binboğa Kurt, B. Koca, T. Rahman, F. Conforti, L. Pala, G. Bianchini, C. Criscitiello, G. Curigliano, A.C. Garrido-Castro, S.K. Kabraji, A.G. Waks, E.A. Mittendorf, S.M. Tolaney
Clinicopathological features and genomics of ER-positive/HER2-negative breast cancer relapsing on adjuvant abemaciclib
2025 C. Corti, A.R. Martin, P.T. Kurnia, J. Gómez Tejeda Zañudo, D.L. Abravanel, M.E. Hughes, T. Parker, P. Tarantino, G. Curigliano, T.A. King, E.A. Mittendorf, N.U. Lin, S.M. Tolaney
Response to Letter to the Editor Re: Impact of the Prosigna assay on neoadjuvant treatment decision making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational study
2025 C. Corti, S.M. Tolaney
Recent Advances in Immune Checkpoint Inhibitors for Triple-Negative Breast Cancer
2025 C. Corti, B. Koca, T. Rahman, E.A. Mittendorf, S.M. Tolaney
Impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational study
2025 C. Corti, X. Chu, P. Exman, D.M. Kline, N.M. Priedigkeit, E.L. Mayer, A.G. Waks, M.E. Hughes, D.L. Abravanel, A. Giordano, G. Curigliano, N.U. Lin, T.A. King, R.M. Jeselsohn, D.K. Manning, D.A. Dillon, E.A. Mittendorf, N. Tayob, S.M. Tolaney
ASO Author Reflections: Disparities in Refusal of Adjuvant Radiation for Breast-Conserving Therapy in the United States
2025 R.S. Bhadouriya, R.V. Mantena, A. Hammond, K. Lapen, C. Corti, P.M.G. Santos, U. Jain, E.C. Dee
Disparities in Refusal of Adjuvant Radiation for Breast-Conserving Therapy in the USA
2025 R. Bhadouriya, R.V. Mantena, J.P. Selvakumar, P. Yadav, T.A. Patel, B. Jain, A. Hammond, K. Lapen, C. Corti, P.M.G. Santos, U. Jain, E.C. Dee
Global disparities in artificial intelligence-based mammogram interpretation for breast cancer: A scientometric analysis of representation, trends, and equity
2025 I.A. Miyawaki, I. Banerjee, F. Batalini, C.A. Campello Jorge, L.A. Celi, M. Cobanaj, E.C. Dee, J.W. Gichoya, Z. Kaffey, M.R. Lloyd, L. Mccullum, S. Ranganathan, C. Corti
Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study
2025 L. Provenzano, M.V. Dieci, G. Curigliano, M. Giuliano, A. Botticelli, M. Lambertini, G. Rizzo, R. Pedersini, M. Sirico, N. La Verde, A. Gennari, A. Zambelli, A. Toss, M. Piras, M. Giordano, B. Tagliaferri, D. Generali, D. Sartori, D. Miliziano, A. Menichetti, F. Ligorio, C. Zurlo, G. Griguolo, P.P. Berton Giachetti, V. Faso, C. Corti, E. Chiappe, S. Scagnoli, S. Pisegna, C. Capasso, C. De Angelis, G. Arpino, C. Criscitiello, V. Guarneri, G. Pruneri, L. Mariani, C. Vernieri
Systemic Therapy in Breast Cancer
2024 C. Corti, H. Batra-Sharma, M. Kelsten, R.A. Shatsky, A.C. Garrido-Castro, W.J. Gradishar
Second Malignancy Probabilities in Patients With Breast Cancer Treated With Conventional Versus Hypofractionated External Beam Radiation Therapy in the Adjuvant Setting
2024 T.A. Patel, B. Jain, H.L. Cho, C. Corti, N. Vapiwala, F. Chino, J.E. Leeman, E.C. Dee
Cardiotoxicity of Agents Used in Patients With Breast Cancer
2024 P. Zagami, D. Trapani, E. Nicolò, C. Corti, C. Valenza, C. Criscitiello, G. Curigliano, L.A. Carey
Checkpoint inhibition for early-stage hormone receptor-positive breast cancer
2024 I. Schlam, C. Corti, S. Sammons, E.A. Mittendorf, S.M. Tolaney
Can we ensure a safe and effective integration of language models in oncology?
2024 C. Corti, L.A. Celi
Advancing equitable and personalized cancer care: Novel applications and priorities of artificial intelligence for fairness and inclusivity in the patient care workflow
2024 M. Cobanaj, C. Corti, E.C. Dee, L. Mccullum, L. Boldrini, I. Schlam, S.M. Tolaney, L.A. Celi, G. Curigliano, C. Criscitiello
A Comprehensive Review of the Growing Landscape of Endocrine and Biologic Treatments for Hormone Receptor-positive Breast Cancer
2024 D. Zhang, A. Ishag-Osman, C. Corti, P. Tarantino, L. Schlam
Exploring the utility and limitations of ChatGPT in scientific literature searches
2023 C. Corti, G. Castellano, G. Curigliano